Pre-made Elipovimab benchmark antibody ( Whole mAb, anti-HIV-1 gp120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the targeted elimination of HIV infected cells and is as of 2020 in phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-171-1mg	1mg	3090
GMP-Bios-ab-171-10mg	10mg	Inquiry
GMP-Bios-ab-171-100mg	100mg	Inquiry
GMP-Bios-ab-171-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody
INN Name	Elipovimab
Target	HIV-1 gp120
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	4fq1:HL/4jy4:BA/4fqc:HL
Year Proposed	2018
Year Recommended	2019
Companies	Gilead Sciences
Conditions Approved	na
Conditions Active	HIV infections
Conditions Discontinued	na
Development Tech	na